Curapath has entered into an exclusive license agreement with Calusa Bio, LLC, further strengthening its PEG alternative toolbox with a novel and differentiated technology. This strategic...
VALENCIA, SPAIN, SEPTEMBER 2, 2025 At Curapath, our mission has always been to push the boundaries of non-viral drug delivery. Today, we are proud to announce...
The CDMO journey is never just operational, it’s human. In this 7-question Q&A, Philippe Clavel, CEO of Curapath, shares his reflections on the first half of...
